1.Forouzanfar MH，Foreman KJ，Delossantos AM，et al .Breast and cervical cancer in 187 countries between 1980 and 2010：a systematic analysis［J］. Lancet，2011，378（9801）：1461-1484.

2.Perou CM . Molecular portraits of human breast tumours［J］. Nature，2000，406（6797）：747-752.

3.Skalicka H，Pudil R，Gregor P. Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines：Prepared by the Czech Society of Cardiology［J］. CorEt Vasa，2017.

4.CuriglianoG.Cardiovascular toxicity induced by chemotherapy，targeted agents and radiotherapy：ESMO Clinical Practice Guidelines［J］. Ann Oncol，2012，23（7）：vii155-vii166.

5.SH Armenian. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers：American Society of Clinical Oncology Clinical Practice Guideline［J］. Journal of Clinical Oncology，2017，35（8）：893.

6.Jose LZ，PartizioL，Daniel RM，et al. 2016 ESC Position On cancer treatment sand cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines［J］. European Journal of Heart Failure，2017，19：9-42.

7.Cardinale D，Colombo A，Lamantia G， et al. Anthracycline-induced cardiomyopathy：clinical relevance and response to pharmacologic therapy［J］. J Am CollCardiol，2010，55（3）：213-220.